NcXHF

BIOMARKER-DRIVEN THERAPY IN MYELOMA
[carboxy-terminal telopeptide of type-I collagen (ICTP), aminoterminal
collagen type-I telopeptide (NTx), and deoxypyridinoline
(Dpd)] in MGUS and multiple myeloma. Eur J Haematol. 2002;69:
37-42.
52. Abildgaard N, Brixen K, Kristensen JE, et al. Comparison of fıve biochemical
markers of bone resorption in multiple myeloma: elevated
pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression
of the bone disease during standard chemotherapy. Br J
Haematol. 2003;120:235-242.
53. Jakob C, Sterz J, Liebisch P, et al. Incorporation of the bone marker
carboxy-terminal telopeptide of type-1 collagen improves prognostic
information of the International Staging System in newly diagnosed
symptomatic multiple myeloma. Leukemia. 2008;22:1767-1772.
54. Schütt P, Rebmann V, Brandhorst D, et al. The clinical signifıcance of
soluble human leukocyte antigen class-I, ICTP, and RANKL molecules
in multiple myeloma patients. Hum Immunol. 2008;69:79-87.
55. Christenson RH. Biochemical markers of bone metabolism: an overview.
Clin Biochem. 1997;30:573-593.
56. Terpos E, Politou M, Szydlo R, et al. Autologous stem cell transplantation
normalizes abnormal bone remodeling and sRANKL/osteoprotegerin
ratio in patients with multiple myeloma. Leukemia. 2004;18:1420-
1426.
57. Dowling P, Hayes C, Ting KR, et al. Identifıcation of proteins found to
be signifıcantly altered when comparing the serum proteome from Multiple
Myeloma patients with varying degrees of bone disease. BMC
Genomics. 2014;15:904.
58. Heuck CJ, Mehta J, Bhagat T, et al. Myeloma is characterized by stagespecifıc
alterations in DNA methylation that occur early during myelomagenesis.
J Immunol. 2013;190:2966-2975.
59. Walker BA, Wardell CP, Chiecchio L, et al. Aberrant global methylation
patterns affect the molecular pathogenesis and prognosis of multiple
myeloma. Blood. 2011;117:553-562.
60. Kaiser MF, Johnson DC, Wu P, et al. Global methylation analysis identifıes
prognostically important epigenetically inactivated tumor suppressor
genes in multiple myeloma. Blood. 2013;122:219-226.
61. Marango J, Shimoyama M, Nishio H, et al. The MMSET protein is a
histone methyltransferase with characteristics of a transcriptional corepressor.
Blood. 2008;111:3145-3154.
62. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes
associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S
A. 2008;105:12885-12890.
63. Dimopoulos K, Gimsing P, Grønbæk K. The role of epigenetics in the
biology of multiple myeloma. Blood Cancer J. 2014;4:e207.
64. Pérez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify
risk of progression in monoclonal gammopathy of uncertain signifıcance
and smoldering multiple myeloma based on multiparameter flow
cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586-
2592.
65. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light
chain ratio is an independent risk factor for progression of smoldering
(asymptomatic) multiple myeloma. Blood. 2008;111:785-789.
66. Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary molecular
cytogenetic abnormalities and risk of progression in smoldering multiple
myeloma. Leukemia. 2013;27:1738-1744.
67. Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma
is independently determined by the chromosomal abnormalities
del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol.
2013;31:4325-4332.
68. Davies FE, Dring AM, Li C, et al. Insights into the multistep transformation
of MGUS to myeloma using microarray expression analysis.
Blood. 2003;102:4504-4511.
69. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profıling
of multiple myeloma, monoclonal gammopathy of undetermined signifıcance,
and normal bone marrow plasma cells. Blood. 2002;99:1745-
1757.
70. Zhan F, Barlogie B, Arzoumanian V, et al. Gene-expression signature of
benign monoclonal gammopathy evident in multiple myeloma is linked
to good prognosis. Blood. 2007;109:1692-1700.
71. Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging
predictors of myeloma progression from asymptomatic monoclonal
gammopathies (SWOG S0120). Blood. 2014;123:78-85.
72. Bhutani M, Turkbey B, Tan E, et al. Bone marrow angiogenesis in myeloma
and its precursor disease: a prospective clinical trial. Leukemia.
2014;28:413-416.
73. Hillengass J, Fechtner K, Weber MA, et al. Prognostic signifıcance of
focal lesions in whole-body magnetic resonance imaging in patients
with asymptomatic multiple myeloma. J Clin Oncol. 2010;28:1606-1610.
74. Merz M, Hielscher T, Wagner B, et al. Predictive value of longitudinal
whole-body magnetic resonance imaging in patients with smoldering
multiple myeloma. Leukemia. 2014;28:1902-1908.
75. Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratifıcation
in multiple myeloma. Leukemia. 2014;28:269-277.
76. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed
symptomatic multiple myeloma: updated Mayo Stratifıcation of
Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
Mayo Clin Proc. 2009;84:1095-1110.
77. Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed
symptomatic multiple myeloma: updated Mayo Stratifıcation of Myeloma
and Risk-Adapted Therapy (mSMART) consensus guidelines
2013. Mayo Clin Proc. 2013;88:360-376.
78. Moreau P, Garban F, Attal M, et al. Long-term follow-up results of
IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation
with autologous transplantation in high-risk de novo multiple
myeloma. Blood. 2008;112:3914-3915.
79. Auner HW, Szydlo R, van Biezen A, et al. Reduced intensityconditioned
allogeneic stem cell transplantation for multiple myeloma
relapsing or progressing after autologous transplantation: a study by the
European Group for Blood and Marrow Transplantation. Bone Marrow
Transplant. 2013;48:1395-1400.
80. Boyd KD, Pawlyn C, Morgan GJ, et al. Understanding the molecular
biology of myeloma and its therapeutic implications. Expert Rev Hematol.
2012;5:603-617.
81. Landgren O, Morgan GJ. Biologic frontiers in multiple myeloma: from
biomarker identifıcation to clinical practice. Clin Cancer Res. 2014;20:
804-813.
82. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations
for tumor MARKer prognostic studies (REMARK). Nat Clin Pract
Urol. 2005;2:416-422.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e503